JP2013116921A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013116921A5 JP2013116921A5 JP2013055718A JP2013055718A JP2013116921A5 JP 2013116921 A5 JP2013116921 A5 JP 2013116921A5 JP 2013055718 A JP2013055718 A JP 2013055718A JP 2013055718 A JP2013055718 A JP 2013055718A JP 2013116921 A5 JP2013116921 A5 JP 2013116921A5
- Authority
- JP
- Japan
- Prior art keywords
- cyp1a2
- pirfenidone
- composition
- inhibitor
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 39
- 229960003073 pirfenidone Drugs 0.000 claims 36
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims 26
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 24
- 239000003112 inhibitor Substances 0.000 claims 20
- 230000003389 potentiating effect Effects 0.000 claims 18
- 208000006104 Cytochrome P-450 CYP1A2 Inhibitors Diseases 0.000 claims 17
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 12
- 238000002560 therapeutic procedure Methods 0.000 claims 8
- 229960002549 enoxacin Drugs 0.000 claims 7
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims 7
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 7
- 229960004038 fluvoxamine Drugs 0.000 claims 7
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims 6
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims 6
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 6
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims 6
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 claims 6
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 6
- 108090000790 Enzymes Proteins 0.000 claims 6
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 claims 6
- 229960005260 amiodarone Drugs 0.000 claims 6
- 229960003405 ciprofloxacin Drugs 0.000 claims 6
- 229940088598 enzyme Drugs 0.000 claims 6
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 claims 6
- 229960000203 propafenone Drugs 0.000 claims 6
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 claims 5
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 230000036407 pain Effects 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 2
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 201000008275 breast carcinoma Diseases 0.000 claims 2
- 238000011260 co-administration Methods 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 claims 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 1
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 claims 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 102000003820 Lipoxygenases Human genes 0.000 claims 1
- 108090000128 Lipoxygenases Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 206010025180 Lymph node fibrosis Diseases 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060932 Postoperative adhesion Diseases 0.000 claims 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 206010037075 Protozoal infections Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 230000003510 anti-fibrotic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000005000 autoimmune gastritis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000001969 capillary hemangioma Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000008406 drug-drug interaction Effects 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000002865 osteopetrosis Diseases 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26681509P | 2009-12-04 | 2009-12-04 | |
| US61/266,815 | 2009-12-04 | ||
| US12/684,879 | 2010-01-08 | ||
| US12/684,879 US7816383B1 (en) | 2009-12-04 | 2010-01-08 | Methods of administering pirfenidone therapy |
| EP10250379A EP2324831B1 (en) | 2009-12-04 | 2010-03-03 | Pirfenidone therapy avoiding fluvoxamine |
| EP10250379.4 | 2010-03-03 | ||
| US31067910P | 2010-03-04 | 2010-03-04 | |
| US61/310,679 | 2010-03-04 | ||
| CA2,710,358 | 2010-08-17 | ||
| CA2710358A CA2710358C (en) | 2009-12-04 | 2010-08-17 | Methods of administering pirfenidone therapy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539128A Division JP2012532934A (ja) | 2009-12-04 | 2010-12-03 | ピルフェニドン療法を施す方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017110731A Division JP2017145262A (ja) | 2009-12-04 | 2017-06-05 | ピルフェニドン療法を施す方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013116921A JP2013116921A (ja) | 2013-06-13 |
| JP2013116921A5 true JP2013116921A5 (https=) | 2014-01-23 |
| JP6193592B2 JP6193592B2 (ja) | 2017-09-06 |
Family
ID=42941192
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539128A Pending JP2012532934A (ja) | 2009-12-04 | 2010-12-03 | ピルフェニドン療法を施す方法 |
| JP2013055718A Active JP6193592B2 (ja) | 2009-12-04 | 2013-03-18 | ピルフェニドン療法を施す方法 |
| JP2017110731A Pending JP2017145262A (ja) | 2009-12-04 | 2017-06-05 | ピルフェニドン療法を施す方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539128A Pending JP2012532934A (ja) | 2009-12-04 | 2010-12-03 | ピルフェニドン療法を施す方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017110731A Pending JP2017145262A (ja) | 2009-12-04 | 2017-06-05 | ピルフェニドン療法を施す方法 |
Country Status (35)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| JP6021117B2 (ja) | 2011-01-31 | 2016-11-02 | ジェノア ファーマシューティカルズ，インク． | エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用 |
| US20130150426A1 (en) * | 2011-11-22 | 2013-06-13 | Intermune, Inc. | Methods of diagnosing and treating idiopathic pulmonary fibrosis |
| CA2819967C (en) * | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| CN103800325A (zh) * | 2012-11-12 | 2014-05-21 | 张康 | 吡非尼酮的新用途 |
| EP2968292A4 (en) | 2013-03-15 | 2016-11-23 | Intermune Inc | METHOD FOR IMPROVING MICROVASCULAR INTEGRITY |
| NZ760541A (en) | 2014-01-10 | 2022-08-26 | Avalyn Pharma Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| WO2016044153A1 (en) * | 2014-09-18 | 2016-03-24 | Rush University Medical Center | Methods for preventing or treating osteoarthritis |
| ES2890492T3 (es) | 2015-07-20 | 2022-01-20 | Acadia Pharm Inc | Métodos para preparar N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida y su sal de tartrato y forma polimórfica C |
| US10582726B2 (en) * | 2015-10-21 | 2020-03-10 | Rai Strategic Holdings, Inc. | Induction charging for an aerosol delivery device |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
| EP3615028A1 (en) | 2017-04-28 | 2020-03-04 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| JP2020520380A (ja) * | 2017-05-16 | 2020-07-09 | ボウ リバー エルエルシー | 処置法 |
| US10857144B2 (en) | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
| US20220143011A1 (en) | 2017-05-16 | 2022-05-12 | Bow River LLC | Methods of treatment with cyp3a4 substrate drugs |
| EP3675827A1 (en) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
| EP3908668A4 (en) | 2019-01-11 | 2022-11-09 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR PREDICTING THE DECREASE IN LUNG FUNCTION IN IDIOPATHIC LUNG FIBROSIS |
| WO2021057599A1 (zh) * | 2019-09-26 | 2021-04-01 | 深圳先进技术研究院 | 吡非尼酮在制备防治类风湿性关节炎的药物中的应用 |
| KR20220109439A (ko) | 2019-12-04 | 2022-08-04 | 이도르시아 파마슈티컬스 리미티드 | 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합 |
| US12569481B2 (en) | 2020-06-12 | 2026-03-10 | Vanderbilt University | Methods of treatment for gastrointestinal motility disorders |
| KR20230107269A (ko) * | 2020-11-12 | 2023-07-14 | 파르바리스 게엠베하 | 혈관부종의 예방 및 치료 |
| CN119630395A (zh) | 2022-02-28 | 2025-03-14 | 努福米克斯技术有限公司 | 用于治疗特发性肺纤维化的组合物和方法 |
| CN115282151B (zh) * | 2022-08-23 | 2023-06-09 | 黑龙江护理高等专科学校 | 一种拉米替隆的应用 |
| GB2628348A (en) * | 2023-03-20 | 2024-09-25 | Ontrack Therapeutics Ltd | Amelioration of drug-drug interactions |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02215719A (ja) * | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
| US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| WO1998014169A1 (en) | 1996-09-30 | 1998-04-09 | Brigham & Women's Hospital | Methods and compounds for treatment of abnormal uterine bleeding |
| EP1551369A4 (en) | 2002-08-28 | 2007-05-09 | Intermune Inc | COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES |
| JP4542743B2 (ja) * | 2002-12-26 | 2010-09-15 | Ｋｄｌ株式会社 | ピリドン誘導体の溶液状医薬組成物 |
| WO2005013917A2 (en) | 2003-02-28 | 2005-02-17 | Intermune, Inc. | Combination therapy for treating alphavirus infection and liver fibrosis |
| CN101039957A (zh) | 2003-05-16 | 2007-09-19 | 因特缪恩公司 | 合成的趋化因子受体配体及其使用方法 |
| US20070092488A1 (en) | 2003-05-16 | 2007-04-26 | Intermune Inc. | Methods of treating idiopathic pulmonary fibrosis |
| US20070053877A1 (en) | 2003-08-21 | 2007-03-08 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| CN1846699A (zh) | 2005-04-13 | 2006-10-18 | 中南大学湘雅医院 | 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用 |
| ES2524922T3 (es) | 2005-05-10 | 2014-12-15 | Intermune, Inc. | Derivados de piridona para modular el sistema de proteína cinasa activada por estrés |
| AU2006276246B2 (en) | 2005-07-25 | 2012-09-27 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
| NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| ATE551057T1 (de) | 2005-10-31 | 2012-04-15 | Intermune Inc | Zusammensetzungen von pirfenidon/toll-like rezeptor (tlr)-antagonisten und verfahren zu ihrer verwendung zur stimulierung der produktion des granulozyten-kolonie-stimulierenden faktors (g-csf) |
| US20070203202A1 (en) | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
| US20080003635A1 (en) | 2006-06-12 | 2008-01-03 | Intermune, Inc. | High Throughput Collagen Synthesis Assay |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| SI2124945T1 (sl) | 2006-12-18 | 2011-08-31 | Intermune Inc | Postopek dajanja terapije s pirfenidonom pacientu |
| US20080287508A1 (en) | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| US7566729B1 (en) | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
| US8084475B2 (en) | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
| US7816383B1 (en) * | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| CA2819967C (en) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| US9621933B2 (en) | 2015-03-27 | 2017-04-11 | Ericsson Ab | System and method for providing VOD content in a switched digital video network using unicast ABR streaming |
-
2010
- 2010-01-08 US US12/684,879 patent/US7816383B1/en active Active
- 2010-03-03 PL PL10250379T patent/PL2324831T3/pl unknown
- 2010-03-03 EP EP11006411A patent/EP2441455A1/en not_active Withdrawn
- 2010-03-03 SI SI201030012T patent/SI2324831T1/sl unknown
- 2010-03-03 AT AT10250379T patent/ATE526024T1/de active
- 2010-03-03 RS RS20110572A patent/RS52102B/sr unknown
- 2010-03-03 PT PT10250379T patent/PT2324831E/pt unknown
- 2010-03-03 ES ES10250379T patent/ES2395155T3/es active Active
- 2010-03-03 DK DK10250379.4T patent/DK2324831T3/da active
- 2010-03-03 EP EP10250379A patent/EP2324831B1/en not_active Revoked
- 2010-08-17 CA CA2710358A patent/CA2710358C/en active Active
- 2010-08-23 AU AU2010212490A patent/AU2010212490B8/en not_active Revoked
- 2010-10-08 US US12/901,245 patent/US7910610B1/en active Active
- 2010-12-03 PH PH1/2012/500733A patent/PH12012500733A1/en unknown
- 2010-12-03 GE GEAP201012775A patent/GEP20166455B/en unknown
- 2010-12-03 JP JP2012539128A patent/JP2012532934A/ja active Pending
- 2010-12-03 MA MA35025A patent/MA33894B1/fr unknown
- 2010-12-03 KR KR1020117018447A patent/KR20110095976A/ko not_active Ceased
- 2010-12-03 MY MYPI2012002462A patent/MY184914A/en unknown
- 2010-12-03 TW TW099142292A patent/TWI373465B/zh not_active IP Right Cessation
- 2010-12-03 WO PCT/US2010/058943 patent/WO2011069094A1/en not_active Ceased
- 2010-12-03 US US13/513,485 patent/US20130030024A1/en not_active Abandoned
- 2010-12-03 BR BR112012014108A patent/BR112012014108A8/pt not_active IP Right Cessation
- 2010-12-03 EP EP10835207.1A patent/EP2506850B1/en not_active Revoked
- 2010-12-03 MX MX2012004662A patent/MX2012004662A/es active IP Right Grant
- 2010-12-03 EP EP13176914.3A patent/EP2653162B1/en not_active Revoked
- 2010-12-03 EA EA201200559A patent/EA035566B1/ru not_active IP Right Cessation
- 2010-12-03 CN CN2010800519935A patent/CN102811719A/zh active Pending
- 2010-12-03 NZ NZ599247A patent/NZ599247A/en not_active IP Right Cessation
- 2010-12-03 PL PL10835207T patent/PL2506850T3/pl unknown
- 2010-12-03 KR KR1020127020908A patent/KR20120097418A/ko not_active Ceased
- 2010-12-03 SG SG2012039632A patent/SG181129A1/en unknown
- 2010-12-03 AP AP2012006339A patent/AP3155A/xx active
- 2010-12-03 SG SG10201502116PA patent/SG10201502116PA/en unknown
- 2010-12-03 KR KR1020177026252A patent/KR20170109079A/ko not_active Ceased
- 2010-12-03 CN CN201510395444.4A patent/CN105168210A/zh active Pending
- 2010-12-03 PE PE2012000475A patent/PE20121502A1/es not_active Application Discontinuation
-
2011
- 2011-03-16 US US13/049,894 patent/US8013002B2/en active Active
- 2011-03-31 AU AU2011201462A patent/AU2011201462B2/en not_active Revoked
- 2011-09-02 US US13/224,589 patent/US8318780B2/en active Active
- 2011-09-26 US US13/244,711 patent/US20120015985A1/en not_active Abandoned
- 2011-11-22 CY CY20111101133T patent/CY1112077T1/el unknown
- 2011-12-21 HR HR20110959T patent/HRP20110959T1/hr unknown
-
2012
- 2012-03-08 SM SM201200009T patent/SMT201200009B/it unknown
- 2012-04-04 IL IL219053A patent/IL219053B/en active IP Right Review Request
- 2012-04-10 ZA ZA2012/02555A patent/ZA201202555B/en unknown
- 2012-04-26 CR CR20120207A patent/CR20120207A/es unknown
- 2012-06-01 TN TNP2012000280A patent/TN2012000280A1/en unknown
-
2013
- 2013-03-18 JP JP2013055718A patent/JP6193592B2/ja active Active
-
2014
- 2014-08-08 US US14/454,980 patent/US20140350060A1/en not_active Abandoned
-
2016
- 2016-05-23 HK HK16105853.7A patent/HK1217903A1/zh unknown
- 2016-06-10 US US15/179,279 patent/US20160303098A1/en not_active Abandoned
-
2017
- 2017-01-23 US US15/412,923 patent/US20170128429A1/en not_active Abandoned
- 2017-06-05 JP JP2017110731A patent/JP2017145262A/ja active Pending
- 2017-11-10 US US15/809,511 patent/US20180064695A1/en not_active Abandoned
-
2018
- 2018-06-21 IL IL260196A patent/IL260196A/en unknown
- 2018-06-27 US US16/020,508 patent/US20180311221A1/en not_active Abandoned
-
2019
- 2019-02-22 US US16/283,270 patent/US20190183872A1/en not_active Abandoned
- 2019-10-10 US US16/598,785 patent/US20200038387A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013116921A5 (https=) | ||
| RU2015111259A (ru) | Способы проведения терапии пирфенидоном | |
| HRP20110959T1 (hr) | Pirfenidonska terapija kojom se izbjegava upotreba fluvoksamina | |
| HRP20110853T1 (hr) | Pirfenidonska terapija i induktori citokroma p450 | |
| PH12018500765A1 (en) | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | |
| JP2012532112A5 (https=) | ||
| WO2009080836A3 (en) | Macrocyclic indoles as hepatitis c virus inhibitors | |
| JP2012507566A5 (https=) | ||
| JP2019515952A5 (https=) | ||
| CA2491895A1 (en) | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases | |
| JP2008528466A5 (https=) | ||
| JP2018507877A5 (https=) | ||
| JP2019519598A5 (https=) | ||
| JP2014521688A5 (https=) | ||
| JP2019517487A5 (https=) | ||
| MY197018A (en) | Substituted tricyclics and method of use | |
| ME01515B (me) | PIRIMIDINSKI DERIVATI ZA TRETMAN ASTME, HOBP, ALERGIJSKOG RINITISA, ALERGIJSKOG KONJUNKTIVITISA, ATOPIČNOG DERMATITISA, RAKA, HEPATITISA B, HEPATITISA C, HIV-a, HPV-a, BAKTERIJSKIH INFEKCIJA I DERMATOZE | |
| MX2017005681A (es) | Cromanos sustituidos y metodo de uso. | |
| JP2016535795A5 (https=) | ||
| JP2016517417A5 (https=) | ||
| TN2017000535A1 (en) | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| JP2012510458A5 (https=) | ||
| MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
| JP2017509586A5 (https=) | ||
| EA023824B1 (ru) | ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) |